The Benefits of Nicotine

014What your doctor doesn’t want you to know about nicotine.

So I’m writing a blog about the benefits of nicotine.  I mean, I’m supposed to tell people not to smoke. That’s what doctors do, right? Already I worry about the consequences: e-cigarette companies will declare me a hero, yes, but my colleagues will ostracize me, and the anti-tobacco mafia will flatten me dead before I can upload this article. Strange thing is there are benefits to nicotine.  Don’t get me wrong.  Tobacco is BAD for you.

The scene unfolds.  Let me warn you: I’ve got a good imagination.  I’m walking through one of those top-secret government buildings, the ones with whitewashed walls and doors that require a hose-down before allowing passage – where there’s a big sign reading, “Beware of Carcinogenic Chemicals: Hazmat Suits Required.”  Alternatively, I’ve been blind-folded and flown to a secret warehouse in Colombia, where I now stand amidst a gaggle of Big Tobacco engineers – and a vial of clear fluid in my hand.  In this version of the story, I’ve been paid a million dollars to write this blog.  Whatever the case, money or not, someone utters three important words: “This is nicotine.”

Here it is: an anticlimactic, boring vial of clear liquid.  What, the fountain of tainted youth?  The essence of venomous glory?  Shouldn’t it fizz through the testtube and melt my hand away?  Shouldn’t I die on the spot?  Oh, the horror.


Okay, you’ve got the image.  This stuff’s led millions of people to their deaths — and I’m about to sing its praises.  (That’s my second disclaimer: I promise it’s the last.)

So what are the benefits of nicotine?  If you want articles cited and literature that supports everything I’m about to tell you, please see the end of this article.  Keep in mind it’s a biased batch of information: I’ve only included the ones that support what I’m about to say.  For those who want everything in a nutshell, start here and keep reading.


021There are at least five diseases or disorders with evidence supporting the effectiveness of nicotine in either minimizing symptoms or preventing the illness altogether.  See bibliography at the end of this article for more information.

Parkinson’s disease is a neurodegenerative disorder which leads to progressive loss of control over movement.  Symptoms include tremor, stiffness, slowness, impaired balance, a shuffling gait, problems eating, and eventually dementia.  Studies suggest that smokers are less likely to get Parkinson’s disease than non-smokers.  The benefits of tobacco for avoiding Parkinson’s seems to be linked to the amount of tobacco a person uses. That is, the more tobacco consumed, the more beneficial it is to the patient.  Of note, ex-smokers seem to have a lower risk of contracting the disease compared to nonsmokers.

Ulcerative Colitis (UC) is a digestive tract disorder caused by inflammation of the colon’s inner lining and the rectal wall, which become red, swollen, and ulcerated.  This causes bouts of severe abdominal pain, rectal bleeding, and diarrhea; serious complications include intestinal blockage, liver disease, cancer, and death.  Studies suggest UC is an illness of non and ex-smokers.  Even passive smoking seems to reduce the risk.  Among people with UC, those who smoke typically have later onset, fewer exacerbations, need less medication, and require fewer surgeries.

Alzheimer’s Disease is marked by memory problems that affect an individual’s abilities to take care of himself.  The mechanism behind this disease is related to the neurotransmitter acetylcholine, the substance found at the nicotinic receptors in the brain.  Studies suggest that nicotine improves attention, memory, thinking, and performance in people with Alzheimer’s.  As an aside, nicotine has even been found helpful in memory and attention in people who don’t have dementia. In one study, scientists tested pilots by giving them (1) nicotine gum, (2) Aricept (a medication used for Alzheimer’s Disease), (3) a bit of alcohol eight hours before their flight, or (4) nothing they wouldn’t usually take. I’m not sure about the ethics of giving alcohol to pilots, but the results were fascinating: those that took Aricept or nicotine demonstrated superior attention, learning, and visual memory than those who drank or took nothing.

Tourette’s Syndrome is marked the presence of tics, both physical and vocal.  Studies suggest nicotine gum or patch can diminish tic behaviors by 50% — and that improvement lasts days or weeks after the nicotine is withdrawn.

People with Schizophrenia suffer from hallucinations, delusions, confused thinking, and personality changes that interfere with their ability to live independently.  They tend to be smokers, and they smoke a lot: three packs/day isn’t unusual.  The theory is they’re self-medicating.  Research shows that Schizophrenics who smoke do better on cognitive tests than when they abstain from smoking for a prolonged period of time; that is, when smoking, they demonstrated superior test results in attention, visuospatial and working memory, sensory gating (ability to ignore unimportant stimuli), and ability to juggle multiple ideas at once).  Of interest, some studies suggest smoking is a protective factor against developing Schizophrenia.

Potential benefits of nicotine aren’t limited to the above-mentioned conditions.  Research suggests the chemical might be helpful for Hyperactivity Disorder and Hypersomnulance (excessive daytime sleepiness), as well as diminish the risk of obesity.


Alex Natalian, Psychiatrist and Author     Alex Natalian is a pseudonym for psychiatrist KRR.

 

 

 


Bibliography/More reading

Allam MF et al. “Young onset Parkinson’s disease and smoking: meta-anaylsis.” Rev Neurol 2003 Dec 16-31; 37(12): 1101-3

Baron JA et al. “Cigarette Smoking and Parkinson’s disease.” Neurology. 1986 Nov; 36(11): 1490-6

Birtwistle J et al. “Does nicotine have beneficial effects in certain diseases?” Br J Nurs 1996 Oct 24-Nov 13; 5(19):1195-202

Fratiglioni L et al. “Smoking and Parkinson’s and Alzheimer’s disease: review of the epidemiological studies.” Behav Brain Res 2000 Aug; 113(1-2): 117-20

Gazzato G et al. “Smoking and Parkinson’s disease.” [article in Italian]. Riv Neurol. 1985 Mar-Apr; 55(2): 79-87

Godwin-Austen RB et al. “Smoking and Parkinson’s disease.” J Neurol Neurosurg Psychiatry. 1982 Jul; 45(7): 577-81

Grandinetti A et al. “Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson’s disease.” Am J Epidemiol. 1994 Jun 15; 139(12): 1129-38

Hellenbrand W et al. “Smoking and Parkinson’s disease: a case-control study in Germany.” Int J Epidemiol. 1997 Apr; 26(2): 328-39

Hernan MA et al. “Cigarette smoking and the incidence of Parkinson’s disease in two prospective studies.” Ann Neurol. 2001 Dec; 50(6): 780-6

Ishikawa A et al. “Effect of smoking in patients with early-onset Parkinson’s Disease.” J Neurol Sci. 1993 Jul; 117(1-2): 28-32

Kelton MC et al. “The effects of Nicotine on Parkinson’s disease.” Brain Cogn. 2000 Jun-Aug; 43(1-3): 274-82

Linert W et al. “In Vitro and in vivo studies investigating possible antioxidant actions of nicotine: revelance to Parkinson’s and Alzheimer’s diseases.” Biochim Biophys Acta. 1999 Jul 7; 1454(2): 143-52

Martyn C et al. “Tobacco, coffee, and Parkinson’s Disease.” BMJ 2003; 326: 561-562 (15 March)

Morens DM et al. “Cigarette smoking and protection from Parkinson’s Disease: false association or etiologic clue?” Neurology. 1995 Jun; 45(6): 1041-51

Newhouse PA et al. “Nicotinic system involvement in Alzheimer’s and Parkinson’s diseases. Implications for therapeutics.” Drugs Aging. 1997 Sep; 11(3): 206-28

Parain K et al. “Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinson toxin.” Brain Res. 2003 Sept 12; 984(1-2):224-32

Quik M et al. “Nicotine receptors and Parkinson’s disease.” Eur J Pharmacol. 2000 Mar 30; 393 (1-3): 223-30

Ross GW et al. “Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson’s disease.” Drugs Aging. 2001; 18(11):797-806

Rusted JM et al. “Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer’s disease and Parkinson’s disease.” Behav Brain Res. 2000 Aug; 113(1-2): 121-9

Scott WK et al. “Family-based case-control study of cigarette smoking and Parkinson disease.” Neurology. 2005 Feb 8; 64(3): 442-7

Shahi GS et al. “Smoking and Parkinson’s disease—a new perspective.” Rev Environ Health. 1991; 9(3): 123-36

Sugita M et al. “Meta-anaylsis for epidemiologic studieson the relationship between smoking and Parkinson’s disease.” J Epidemiol. 2001 Mar; 11(2): 87-94

Tan EK et al. “Dose-dependent protective effects of coffee, tea, and smoking in Parkinson’s disease: a study in ethnic Chinese.” J Neurol Sci. 2003 Dec 15; 216(1): 163-7

Wirdefeldt K et al. “Risk and protective factors for Parkinson’s disease: a study in Swedish twins.” Ann Neurol. 2005 Jan; 57(1): 27-33

Birrenbach T, et al. “Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications.” Inflamm Bowel Dis 2004 Nov; 10(6): 848-59

Birtwistle J, et al. “The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis.” Postgrad Med J. 1996 Dec; 72(854): 714-8

Bustamante M, et al. “Relationship between smoking and colonic involvement in inflammatory bowel disease.” Rev Esp Enferm Dig. 1998 Dec; 90(12): 833-40

Calkins BM, et al. “A meta-analysis of the role of smoking in inflammatory bowel disease.” Dig Dis Sci. 1989 Dec; 34(12): 1841-54

Cosnes J, et al. “Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice.” Best Pract Res Clin Gastroenterology 2004 Jun; 18(3): 481-96

Matri S, et al. “Tobacco and inflammatory bowel disease.” Tunis Med 2000 Dec; 78(12): 693-8 [article in French]

Martins Junior EV, et al. “Smoking and inflammatory bowel disease: an epidemiological case control study.” Arq Gastroenterol 1996 Apr-Jun; 33(2): 74-8. [article in Portuguese]

Pullan RD, et al. “Colonic mucus, smoking, and ulcerative colitis.” Ann R Coll Surg Engl. 1996 Mar; 78(2): 85-91

Rubin DT, et al. “Smoking and inflammatory bowel disease.” Eur J Gastroenterol Hepatol. 2000 Aug; 12(8): 855-62

Thomas GA, et al. “Inflammatory bowel disease and smoking—a review.” Am J Gastroenterol 1998 Feb; 93(2): 144-9

Thomas GA, et al. “Role of smoking in inflammatory bowel disease: implications for therapy.” Postgrad Med J. 2000 May; 76(895): 273-9

Decker MW, et al. J “(s)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II In vivo characterization.” Pharmacol Exp Ther. 1994 Jul; 270(1): 319-28

Dickerson TJ, et al. “Glycation of the amyloid beta-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer’s disease.” Proc Natl Acad Sci USA 2003 Jul 8; 100(14): 8182-7. Epub 2003 Jun 18.

Engeland C, et al. “Nicotine and sensory memory in Alzheimer’s disease: an event-related potential study.” Brain Cogn. 2002 Jul; 49(2): 232-4

Fisher A, et al. “AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer’s disease.” J Mol Neurosci. 2002 Aug-Oct; 19(1-2): 145-53

Fisher A, et al. “M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease: implications in future therapy.” J Mol Neurosci. 2003; 20(3): 349-56

Levin ED, et al. “Persistence of chronic nicotine-induced cognitive facilitation.” Behav Neural Biol. 1992 Sep; 58(2): 152-8

Picciotto MR, et al. “Nicotine receptors in aging and dementia.” J Neurobiol. 2002 Dec; 53(4): 641-55

Mihailescu S, et al. “Nicotine, brain nicotinic receptors, and neuropsychiatric disorders.” Arch Med Res. 2000 Mar-Apr; 31(2): 131-44

Katner SN, et al. “Effects of nicotine and mecamylamine on cognition in rhesus monkeys.” Psychopharmacology (Berl). 2004 Sep; 175(2): 225-40. Epub 2004 Apr 27

Levin ED, et al. “Nicotinic receptor subtypes and cognitive function.” J Neurobiol. 2002 Dec; 53(4): 633-40

Mumenthaler MS, et al. “Psychoactive drugs and pilot performance: a comparison of nicotine, donepezil, and alcohol effects.” Neuropsychopharmacology. 2003 Jul; 28(7): 1366-73. Epub 2003 May 14.

Gatto GJ, et al. TC-1743: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects.” CNS Drug Rev. 2004 Summer; 10(2): 147-66

Letenneur L, et al. “Tobacco consumption and cognitive impairment in elderly people. A population-based study.” Ann Epidemiol. 1994 Nov; 4(6): 449-54

Levin ED, et al. “Nicotine systems and cognitive function.” Psychopharmacology (Berl). 1992; 108(4): 417-31

Levin ED, et al. “Nicotinic treatment for cognitive dysfunction.” Curr Drug Targets CNS Neurol Disord. 2002 Aug; 1(4): 423-31

Mihailescu S, et al. “Nicotine and brain disorders.” Acta Pharmacol Sin. 2000 Feb: 21(2): 97-104

Murray KN, et al. “Nicotine’s effect on neural and cognitive functioning in an aging population.” Aging Ment Health 2002 May; 6(2): 129-38

Newhouse PA, et al. “Effects of nicotinic stimulation on cognitive performance.” Curr Opin Pharmacol. 2004 Feb; 4(1): 36-46

Newhouse P, et al. “Nicotine and nicotinic receptor involvement in neuropsychiatric disorders.” Curr Top Med Chem. 2004; 4(3): 267-82

Rezvani AH, et al. “Cognitive effects of nicotine.” Biol Psychiatry. 2001 Feb 1; 49(3): 258-67

White HK, et al. “Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer’s disease.” Psychopharmacology (Berl). 1999 Apr; 143(2): 158-65

Williams E. “In vitro evidence supporting the therapeutic role of nicotine against neurodegeneration.” In Vivo. 2004 May-Jun; 18(3): 391-9.

Dursum SM, et al. “Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette’s syndrome: an open study.” Psychol Med. 1997 Mar; 27(2): 483-7

Howson AL, et al. “Clinical and attentional effects of acute nicotine treatment in Tourette’s syndrome.” Eur Psychiatry. 2004 Apr; 19(2): 102-12

Dursun SM, et al. “Longlasting improvements of Tourette’s syndrome with transdermal nicotine.” Lancet. 1994 Dec 3; 344(8936): 1577

Dursun SM, et al. “Smoking, nicotine, and psychiatric disorders: evidence for therapeutic role, controversies and implications for future research.” Med Hypotheses. 1999 Feb; 52(2): 101-9

Howson AL, et al. “Clinical and attentional effects of acute treatment in Tourette’s syndrome.” Eur Psychiatry. 2004 Apr; 19(2): 102-12

McConville BJ, et al. “Nicotine potentiation of haloperidol in reducing tic frequency in Tourette’s disorder.” Am J Psychiatry. 1991 Jun; 148(6): 793-4

McConville BJ, et al. “The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette’s disorder.” Biol Psychiatry. 1992 Apr 15; 31(8): 832-40

Mohammed M, et al. “Taken from “Recognition and Management of Tourette’s Syndrome and Tic Disorders.” American Family Physician. 1999 Apr 15: 59(8): http://www.aafp.org.

Orth M. Brain. “Excitability of motor cortex inhibitory circuits in Tourette syndrome before and after single dose nicotine.” 2005 Jun; 125(Pt 6): 1292-300. Epub 2005 Mar 17

Perkins KA, et al. “Society for Research on Nicotine and Tobacco.” Addiction. 1996 Jan; 91(1): 129-44

Sanberg PR, et al. “Nicotine for the treatment of Tourette’s syndrome.” Pharmacol Ther. 1997; 74(1): 21-5

Sanberg PR, et al. “Nicotine potentiates the effects of Haloperidol in animals and patients with Tourette’s syndrome.” Biomed Pharmacother. 1989; 43(1): 19-23

Silver AA, et al. “Case-study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette’s syndrome.” J Am Acad Child Adolesc Psychiatry. 1996 Dec; 35(12): 1631-6

Silver AA, et al. “Transdermal nicotine and haloperidol in Tourette’s disorder: a double-blind placebo-controlled study.” J Clic Psychiatry. 2001 Sep; 62(9): 707-14

Tizabi Y, et al. “Nicotine attenuates DOI-induced head-twitch response in mice: implications for Tourette’s syndrome.” Prog Neuropsychopharmacol Biol Psychiatry. 2001 Oct; 25(7): 1445-57

Adler LE, et al. “Normalization of auditory physiology by cigarette smoking in schizophrenic patients.” Am J Psychiatry. 1993 Dec; 150(12):1856-61

Aguilar MC, et al. “Nicotine dependence and symptoms in schizophrenia: naturalistic study of complex interactions.” Br J Psychiatry. 2005 Mar; 186: 215-21

Araki H, et al. “Neuronal nicotinic receptor and psychiatric disorders: functional and behavioral effects of nicotine.” Jpn J Pharmacol. 2002 Feb; 88(2): 133-8

Avila MT, et al. “Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia.” Neuropsychopharmacology. 2003 Dec; 28(12): 2184-91

Cattapan-Ludewig K, et al. “[Why do schizophrenic patients smoke?]” Nervenarzt. 2005 Mar; 76(3): 287-94. Article in German.

Cocuk Psikiyatrisi AD, et al. “[Smoking and schizophrenia: where is the biological connection?]” Turk Psikiyatri Derg. 2006 Spring; 17(1): 55-64. Article in Turkish.

Dalack GW, et al. “Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings.” Am J Psychiatry. 1998 Nov; 155(11): 1490-501.

Freedman R, et al. “Schizophrenia and nicotinic receptors.” Harv Rev Psychiatry. 1994 Nov-Dec; 2(4): 179-92

George TP, et al. “A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechansisms.” Schizophr Res. 2006 Oct; 87(1-3): 307-15. Epub 2006 Jul 18.

George TP, et al. “Effects of smoking abstinence on visuospatial working memory function in schizophrenia.” Neuropsychopharmacology. 2002 Jan; 26(1): 75-85

Jacobsen LK, et al. “Nicotine effects on brain function and functional connectivity in schizophrenia.” Biol Psychiatry. 2004 Apr 15; 55(8): 850-8

Kumari V, et al. “Influence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia.” Hum Psychopharmacol. 2001 Jn; 16(4): 321-326

Lohr JB, et al. “Smoking and schizophrenia.” Schizophr Res. 1992 Dec; 8(2): 93-102

Martin LF, et al. “Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.” Psychopharmacology (Berl). 2004 Jun; 174(1): 54-64. Epub 2004 Feb 19.

McEvoy JP, et al. “The importance of nicotinic acetylcholine receptors in schizophrenia, bipolar disorder, and Tourette’s syndrome.” Curr Drug Targets CNS Neurol Disord. 2002 Aug; 1(4): 433-42

Olincy A, et al. “Proof-of-concept trial of alpha7 nicotinic agonist in schizophrenia.” Arch Gen Psychiatry. 2006 Jun; 63(6): 630-8.

Postma P, et al. “A behavioral and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia.” Psychopharmacology (Berl). 2006 Mar; 184(3-4): 589-99. Epub 2006 Feb 2.

Sacco KA, et al. “Effects of cigarette smoking on spatial working memory an attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms.” Arch Gen Psychiatry. 2005 Jun; 62(6): 649-59

Sacco KA, et al. “Neuropsychological deficits in nonsmokers with schizophrenia: effects of nicotinic antagonist.” Schizophr Res. 2006 Jul; 85(1-3): 213-21. Eupub 2006 May 4.

Silver H, et al. “Schizophrenic patients who smoke have a faster finger tapping rate than non-smokers.” Eur Neuropsychopharmacol. 2002 Apr; 12(2): 141-4

Smith RC, et al. “Effects of cigarette smoking and nicotinic nasal spray on psychiatric symptoms and cognition in schizophrenia.” Neuropsychopharmacology. 2002 Sep; 27(3): 479-97


Zammit S, et al. “Investigating the association between cigarette smoking and schizophrenia in a cohort study.” Am J Psychiatry. 2003 Dec; 160(12): 2216-21

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s